

Sandro Gentile

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6730715/publications.pdf>

Version: 2024-02-01

37
papers

935
citations

566801

15
h-index

454577

30
g-index

38
all docs

38
docs citations

38
times ranked

1190
citing authors

#	ARTICLE	IF	CITATIONS
1	Comment on the article Determination of insulin-related lipohypertrophy frequency and risk factors in patients with diabetes. <i>Endocrinologia, Diabetes Y Nutrición</i> , 2022, , .	0.1	0
2	The Economic Burden of Insulin Injection-Induced Lipohypertrophy. Role of Education: The ISTERP-3 Study. <i>Advances in Therapy</i> , 2022, 39, 2192-2207.	1.3	8
3	Comparison between Policaptil Gel Retard and Metformin by Testing of Temporal Changes in Patients with Metabolic Syndrome and Type 2 Diabetes. <i>International Journal of Diabetology</i> , 2022, 3, 315-327.	0.9	1
4	Lipohypertrophy in Elderly Insulin-Treated Patients With Type 2 Diabetes. <i>Diabetes Therapy</i> , 2021, 12, 107-119.	1.2	10
5	Role of Structured Education in Reducing Lypodistrophy and its Metabolic Complications in Insulin-Treated People with Type 2 Diabetes: A Randomized Multicenter Case-Control Study. <i>Diabetes Therapy</i> , 2021, 12, 1379-1398.	1.2	15
6	Bruising: A Neglected, Though Patient-Relevant Complication of Insulin Injections Coming to Light from a Real-Life Nationwide Survey. <i>Diabetes Therapy</i> , 2021, 12, 1143-1157.	1.2	7
7	Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis. <i>Advances in Therapy</i> , 2021, 38, 4195-4214.	1.3	3
8	Insulin-induced skin lipohypertrophies: A neglected cause of hypoglycemia in dialysed individuals with diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102145.	1.8	0
9	The Durability of an Intensive, Structured Education-Based Rehabilitation Protocol for Best Insulin Injection Practice: The ISTERP-2 Study. <i>Diabetes Therapy</i> , 2021, 12, 2557-2569.	1.2	13
10	Hundred-year experience with insulin and lipohypertrophy: An unresolved issue. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108924.	1.1	1
11	Insulin-Induced Skin Lipohypertrophy in Type 2 Diabetes: a Multicenter Regional Survey in Southern Italy. <i>Diabetes Therapy</i> , 2020, 11, 2001-2017.	1.2	29
12	<scp>COVID</scp>-19, ketoacidosis and new-onset diabetes: Are there possible cause and effect relationships among them?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2507-2508.	2.2	38
13	The Need for Diabetes Care Customization in the ICU at the Time of SARS-CoV-2 Outbreak. <i>Diabetes Therapy</i> , 2020, 11, 1191-1193.	1.2	7
14	COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be) <i>Tj ETQq0 0 0 rgBT /Overlock 10</i>	1.1	74
15	Insulin-Related Lipohypertrophy in Hemodialyzed Diabetic People: a Multicenter Observational Study and a Methodological Approach. <i>Diabetes Therapy</i> , 2019, 10, 1423-1433.	1.2	12
16	Considerations on lipoatrophic skin lesions far from insulin injection sites. <i>Diabetes Research and Clinical Practice</i> , 2018, 140, 347-350.	1.1	2
17	Insulin related lipodystrophic lesions and hypoglycemia: Double standards?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018, 12, 813-818.	1.8	16
18	Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-10.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Cost saving effects of a short-term educational intervention entailing lower hypoglycaemic event rates in people with type 1 diabetes and lipo-hypertrophy. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 320-321.	1.1	12
20	The complex interplay between clinical and person-centered diabetes outcomes in the two genders. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 41.	1.0	19
21	Lipodystrophy and Associated Risk Factors in Insulin-Treated People With Diabetes. <i>International Journal of Endocrinology and Metabolism</i> , 2016, 14, e33997.	0.3	8
22	Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. <i>Diabetes Care</i> , 2016, 39, 1318-1328.	4.3	116
23	Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear?. <i>Diabetes Therapy</i> , 2016, 7, 401-409.	1.2	45
24	A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. <i>SpringerPlus</i> , 2016, 5, 563.	1.2	68
25	Unexplained Hypoglycaemia and Large Glycaemic Variability: Skin Lipohypertrophy as a Predictive Sign. <i>Sports and Exercise Medicine - Open Journal</i> , 2016, 2, 24-32.	0.3	23
26	A Multicenter Italian Survey on Diabetes Care Units Reveals a Somewhat Slow Attitude in Treatment Guideline Implementation: Are We Dealing With Therapeutic Inertia?. <i>Sports and Exercise Medicine - Open Journal</i> , 2016, 2, 33-44.	0.3	5
27	Însulin treatment of people with diabetes mellitus and chronic liver disease. <i>Annals of Hepatology</i> , 2016, 15, 287-8.	0.6	2
28	Metabolic effects of the association <i>Berberis aristata/Silybum marianum</i> : a preliminary double-blind, placebo-controlled study in obese patients with type 2 diabetes. <i>Nutrafoods</i> , 2015, 14, 181-188.	0.5	6
29	Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. <i>Acta Diabetologica</i> , 2015, 52, 845-853.	1.2	79
30	Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000109.	1.2	7
31	Correlates of diabetes-related distress in type 2 diabetes: Findings from the benchmarking network for clinical and humanistic outcomes in diabetes (BENCH-D) study. <i>Journal of Psychosomatic Research</i> , 2015, 79, 348-354.	1.2	73
32	Interplay among patient empowerment and clinical and person-centered outcomes in type 2 diabetes. The BENCH-D study. <i>Patient Education and Counseling</i> , 2015, 98, 1142-1149.	1.0	43
33	Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 129.	0.4	15
34	Acarbose vs metformin for new-onset type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 104.	5.5	4
35	Different prevalence of metabolic control and chronic complication rate according to the time of referral to a diabetes care unit in the elderly. <i>Acta Diabetologica</i> , 2014, 51, 447-453.	1.2	6
36	Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes. <i>Acta Diabetologica</i> , 2011, 48, 121-125.	1.2	39

#	ARTICLE	IF	CITATIONS
37	A randomized controlled trial of acarbose in hepatic encephalopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 184-191.	2.4	116